PMID- 32614250
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20210512
IS  - 1557-8682 (Electronic)
IS  - 1527-0297 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Dec
TI  - The Prevalence and Risk Factors of High-Altitude Pulmonary Hypertension Among 
      Native Tibetans in Sichuan Province, China.
PG  - 327-335
LID - 10.1089/ham.2020.0022 [doi]
AB  - Gou, Qiling, Rufeng Shi, Xin Zhang, Qingtao Meng, Xinran Li, Xi Rong, Zhabu Gawa, 
      Nage Zhuoma, and Xiaoping Chen. The prevalence and risk factors of high-altitude 
      pulmonary hypertension among native Tibetans in Sichuan Province, China. High Alt 
      Med Biol. 21:327-335, 2020. Background: Studies evaluating the prevalence and 
      risk factors of high-altitude pulmonary hypertension (HAPH) are lacking. 
      Objective: To determine the prevalence of HAPH and its correlated factors among 
      highlanders living 3200 m above sea level in Ganzi Tibetan Autonomous Prefecture, 
      Sichuan Province, China. Methods: This was a single-center, cross-sectional study 
      involving 1129 subjects (mean age 46.6 +/- 14 years, 39% men). In native Tibetans, 
      HAPH was defined as a mean pulmonary artery pressure >30 mmHg as measured by 
      transthoracic echocardiography. Results: HAPH had a crude prevalence of 6.2% and 
      was more prevalent in men than in women (8.6% vs. 4.6%, p = 0.005). Elderly 
      adults were more likely to develop HAPH than young adults (odds ratio 
      [OR] = 5.308, 95% confidence interval [CI] = 2.562-10.993). Highlanders with HAPH 
      had more severe metabolic abnormalities (including elevated blood pressure, blood 
      glucose, blood lipids, BMI, etc., p < 0.05) and significantly increased 
      hemoglobin and hematocrit levels (p < 0.01). In multivariate logistic regression 
      analysis, independent risk factors for HAPH were metabolic syndrome (OR = 3.128, 
      95% CI = 1.110-8.818), age (>60 years vs. <40 years) (OR = 2.924, 95% 
      CI = 1.282-6.669), and decreased SpO(2) (OR = 1.072 per 1-unit decrease; 95% 
      CI = 1.010-1.136). Conclusion: It could be concluded that HAPH was prevalent 
      among 6.2% of native Tibetans in Sichuan Province, China. Increasing age, 
      metabolic syndrome, and decreased SpO(2) were independent predisposing factors 
      for HAPH.
FAU - Gou, Qiling
AU  - Gou Q
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
FAU - Shi, Rufeng
AU  - Shi R
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
FAU - Meng, Qingtao
AU  - Meng Q
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
FAU - Li, Xinran
AU  - Li X
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
FAU - Rong, Xi
AU  - Rong X
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
FAU - Gawa, Zhabu
AU  - Gawa Z
AD  - Luhuo County People's Hospital, Ganzi, People's Republic of China.
FAU - Zhuoma, Nage
AU  - Zhuoma N
AD  - Luhuo County People's Hospital, Ganzi, People's Republic of China.
FAU - Chen, Xiaoping
AU  - Chen X
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200630
PL  - United States
TA  - High Alt Med Biol
JT  - High altitude medicine & biology
JID - 100901183
SB  - IM
MH  - Adult
MH  - Aged
MH  - Altitude
MH  - China/epidemiology
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Hypertension, Pulmonary/epidemiology/etiology
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Risk Factors
MH  - Tibet/epidemiology
MH  - Young Adult
OTO - NOTNLM
OT  - Tibetans
OT  - high-altitude pulmonary hypertension
OT  - hypoxia
OT  - metabolic syndrome
EDAT- 2020/07/03 06:00
MHDA- 2021/05/13 06:00
CRDT- 2020/07/03 06:00
PHST- 2020/07/03 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2020/07/03 06:00 [entrez]
AID - 10.1089/ham.2020.0022 [doi]
PST - ppublish
SO  - High Alt Med Biol. 2020 Dec;21(4):327-335. doi: 10.1089/ham.2020.0022. Epub 2020 
      Jun 30.